Troglitazone directly increases HDL cholesterol levels

Diabetes Care

Volumn 22, Issue 2, 1999, Pages 355-356

  Nozue, Tsuyoshi ^a,b   Michishita, Ichiro ^a   Minagawa, Fuyuki ^a   Genda, Akira ^a  

^a Yokohama Sakae Kyosai Hospital   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TROGLITAZONE;

ADULT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; TREATMENT OUTCOME;

BLOOD GLUCOSE; CHOLESTEROL, HDL; CHROMANS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0032960540     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.2.355     Document Type: Note

References (9)

1. DeFronzo RA: Lilly Lecture 1987: the triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37:667-687, 1988
2. Hansen AP: Effect of troglitazone, a thiazolidinedione, in elderly non-insulin dependent diabetic patients (Abstract). Diabetologia 38 (Suppl. 1):A200, 1995
3. Kumar S, Boulton AJM, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P, for the Troglitazone Study Group: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39:701-709, 1996
4. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Effect of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 19:151-156, 1996
5. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma T, Shigeta Y, Kaneko T: Effect of combination therapy of troglitazone and sulfonylureas in patients with type 2 diabetes who were poorly controlled by sulfonylurea therapy alone. Diabet Med 13:365-370, 1996
6. Suter SL, Nolan JJ, Wallace P, Gumbmer B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
7. Yamada N, Akanuma Y, Murase T, Kikuchi M, Yamnouchi T, Miyazaki S, Kawazu S, Iwamoto Y, Kawakami M: Clinical evaluation of a new oral hypoglycemic drug CS-045 in patients with non-insulin dependent diabetes mellitus accompanying hypertriglyceridemia (in Japancse). Rinsho Iyaku 9 (Suppl. 3):165-178, 1993
8. Valiquett T, Huang S, Whitcomb R: Effect of troglitazone monotherapy in patients with NIDDM: a 6-month multicenter study (Abstract). Diabetes 46 (Suppl. 1):43A, 1997
9. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW, The Troglitazone Study Group: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46:433-439, 1997